Akari Therapeutics Announces Release of the Next CEO Corner Segment

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX) announced on Nov 25, 2025 that a new CEO Corner segment is published on the company website. In the video, CEO Abizer Gaslightwala reviews Akari’s innovation in antibody drug conjugates (ADCs), highlights the company’s novel PH1 payload and its dual mechanism of action, and discusses the capabilities of Akari’s next‑generation ADC discovery platform. The segment reiterates the company’s mission to advance differentiated therapies for patients and is available for viewing on the company website.

Access the Akari CEO Corner here

BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced the next CEO Corner segment has been published on the Company’s website. For this CEO Corner segment, Abizer Gaslightwala, CEO of Akari, provides an overview of the Company’s innovation in ADCs, highlighting its novel PH1 payload and its dual mechanism of action. Additionally, Mr. Gaslightwala discusses the growing capabilities of Akari’s next-generation ADC discovery platform and the Company’s mission to advance differentiated therapies for patients.

The CEO Corner segment is now available here.

About Akari Therapeutics

Akari Therapeutics is an oncology biotechnology company developing next-generation spliceosome payload antibody drug conjugates (ADCs). Utilizing its innovative ADC discovery platform, the Company has the ability to generate ADC candidates and optimize them based on the desired application to any target of interest. Unlike current ADCs that use tubulin inhibitors and DNA damaging agents as their payloads, PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. This splicing modulation has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.

For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn.

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908-824-0775
AKTX@jtcir.com    

FAQ

What did Akari Therapeutics announce on Nov 25, 2025 about AKTX?

Akari published a new CEO Corner segment featuring CEO Abizer Gaslightwala discussing ADC innovation.

What topics does the Nov 25, 2025 AKTX CEO Corner cover?

The segment covers the PH1 payload, its dual mechanism, and the next‑generation ADC discovery platform.

How can investors watch the Nov 25, 2025 Akari (AKTX) CEO Corner?

The CEO Corner segment is available to view on Akari Therapeutics’ official company website.

Who speaks in the AKTX CEO Corner released Nov 25, 2025?

The presentation is by CEO Abizer Gaslightwala.

Does the Nov 25, 2025 CEO Corner for AKTX include clinical or financial results?

No; the announcement describes technology and platform updates, not clinical or financial data.

What is the significance of the PH1 payload mentioned in the AKTX CEO Corner?

The CEO highlights PH1 as a novel payload with a described dual mechanism of action for ADC development.